Drugs / FCN-437
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03951116 | Jun 2019 → Dec 2021 | cancer | Fochon Pharmaceuticals, Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCN-437 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03951116 ↗ |
| Action | Inhibit | “FCN-437c is a novel, potent and selective inhibitor of CDK4/6 exhibiting cellular potency against a number of human tumor cell lines.” NCT03951116 ↗ |
| Route | Oral | “FCN-437c will be administered orally.” NCT03951116 ↗ |
| Target | CDK4 | “FCN-437c is a novel, potent and selective inhibitor of CDK4/6 exhibiting cellular potency against a number of human tumor cell lines.” NCT03951116 ↗ |